1. Porwit-MacDonald A, Bjorklund E, Lucio P et al: BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ subsets in normal bone marrow and as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (TALL). Leukemia 14:816-825, 2000.

2. Paietta E: Immunophenotyping of adult leukemia. In Steele GD Jr, Phillips TL, Chabner BA, Gansler TS (eds): American Cancer Society Atlas of Clinical Oncology. Series Volume, Wiernik PH (ed): Adult Leukemias BC Decker, Hamilton, Ont., 2001 (in press).

3. Paietta E, Papenhausen P: Cytogenetic alterations and related molecular consequences in adult leukemia. In Steele GD Jr, Phillips TL, Chabner BA, Gansler TS (eds): American Cancer Society Atlas of Clinical Oncology Series Volume, Adult Leukemias Wiernik PH (ed.): BC Decker, Hamilton, Ont. 2001 (in press)

Dyck JA, Warrell RP Jr, Evans RM et al: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RARa protein. Blood 86:862, 1995.

Falini B, Flenghi L, Fagioli M et al: Immunocytochemical diagnosis of the acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 90:4046, 1997. Harris NL, Jaffe ES, Diebold J et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lym-phoid tissues: Report of the clinical advisory committee meeting (Airlie House, Virginia, November 1997). J Clin Oncol 17:3835, 1999.

Forkner CE: Leukemia and Allied Disorders. Macmillan, New York, 1938.

Bennett JM, Catovsky D, Daniel MT et al: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620, 1985.

Melnick A, Licht JD: Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelo-cytic leukemia. Blood 93:3167, 1999.

Bennett JM, Catovsky D, Daniel MT et al: Proposal for the recognition of minimally differentiated acute myeloid leukemia. Br J Haematol 78:325, 1991.

Goasguen JE, Matsuo T, Cox C et al: Evaluation of the dys-myelopoiesis in 336 patients with de novo acute myeloid leukemia: Major importance of dysgranulopoiesis for remission and survival. Leukemia 6:520, 1992.

Exner M, Thalhammer R, Kapiotis S et al: The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): Does it prove true for M3-variant? Cytometry 42:106, 2000. Sainty D, Liso V, Cantu-Rajnoldi A et al: A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 96:1287, 2000.

Specchia G, Mestice A, Carluccio P et al: Biological features of CD34+ CD2+ acute promyelocytic leukemia (APL). Blood 96:115a, #495,2000.

Paietta E, Neuberg D, Bennett JM et al: Novel definition ofundif-ferentiated (UNDIF) acute myeloid leukemia (AML) by low expression of the CD65s carbohydrate molecule: Analysis of 996 patients from the ECOG database. Blood (Suppl 1):220b, #3723, 1997.

Hurwitz CA, Raimondi SC, Head D et al: Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 80:3182, 1992. Ferrara F, Di Noto R, Annunziata M et al: Immunophenotypic analysis enables the correct prediction of t(8;21) in acute myeloid leukemia. Br J Haematol 102:444, 1998.

Paietta E: Immunophenotyping and P-glycoprotein in APL. In Advances in Blood Disorders, Series Volume: Tallman MS, Avvisati G (eds.) APL: Towards the Curability of Acute Myeloid Leukemia. (in press)

Paietta E, Racevskis J, Neuberg D et al: Expression of CD25 (inter-leukin-2 receptor a chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: Results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Leukemia. 11:1887, 1997.

Borowitz MJ, Rubnitz J, Nash M et al: Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: A Pediatric Oncology Group study. Leukemia 12:1764,1998. De Zen L, Orfao A, Cazzaniga G et al: Quantitative multipara-metric immunophenotyping in acute lymphoblastic leukemia: Correlation with specific genotype I ETV6/AML1 ALLs identification. Leukemia 14:1225, 2000.

22. Murray CK, Estey E, Paietta E et al: CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome? J Clin Oncol 17:293, 1999.

23. Ferrara F, Morabito F, Martino B et al: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelo-cytic leukemia treated with simultaneous all-trans retinoic acid and chemotherapy. J Clin Oncol 18:1295, 2000.

24. Baer MR, Stewart CC, Lawrence D et al: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643, 1997.

25. Paietta E, Andersen J, Yunis J et al: Acute myeloid leukemia expressing the leucocyte integrin CD11b—a new leukemic syndrome with poor prognosis: Result of an ECOG database analysis. Br J Haematol 100:265, 1998.

26. Tucker J, Dorey E, Gregory WM et al: Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 8:47, 1990.

27. Bradstock K, Matthews J, Benson E et al: Prognostic value of immunophenotyping in acute myeloid leukemia. Blood 84:1220,

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment